MTOR and breast cancer: PT of her surgical sample revealed somatic mutations in TP53 and a hemizygous loss of NF2, yielding four possible therapies, including an mTOR inhibitor, everolimus, approved in combination with anti‐hormonal therapy for metastatic BC.